Daniel Sutherby joined Abiomed (Danvers, Massachusetts) as CFO. He previously was with PerkinElmer, most recently as corporate vice president, investor relations, corporate communications and risk management. Charles Haaser, who has served as Abiomed’s interim acting CFO, will continue as corporate controller and principal accounting officer. In other Abiomed news, former Guidant (Indianapolis) President and CEO Ron Dollens has been named to Abiomed’s board of directors. Dollens served as president and CEO of Guidant from the time of its spin-off from Eli Lilly and Co. in early 1995 until his retirement in November. Abiomed develops medical devices des-igned to assist or replace the pumping function of a failing heart.
• Robert Wood has retired as CFO, vice president, treasurer and secretary of Biophan Technologies (West Henrietta, New York). He is succeeded by Darryl Canfield. For the past five years Canfield has been vice president, corporate controller and chief acco-unting officer at Genencor International. Wood will continue to serve the company for a period of time as a financial consultant for special projects and corporate support. Biophan develops technologies design-ed to make biomedical devices safe and image-compatible with the MRI environment.
• Jim Tobin, president and CEO of Boston Scientific (Natick, Massachusetts), has agreed to a request from the board of directors to extend his tenure at the company. The company said in a statement that Tobin plans to remain in his role “for the foreseeable future.” “Jim has presided over a period of exceptional growth, accomplishment and success,” said Warren Rudman, director and chairman of the executive compensation and human resources committee of the board of directors. “He has brought to bear his considerable talents to position Boston Scientific as one of the world’s pre-eminent medical companies. The company aspires to further advance the interests of customers, patients and shareholders, and Jim is clearly the leader who can best help us achieve these aspirations. The board is highly enthusiastic about the company’s prospects under his ongoing leadership.”
• Tim Attebery has been named senior vice president for business development with Cardiovascular Services of America (Brentwood, Tennessee), effective Feb. 1. Attebery has served as CEO of South Carolina Heart Center since 1998. Cardiovascular Services of America develops and operates outpatient cath labs and CT angiography suites in partnership with cardiovascular physicians.
• Thomas Tully has been appointed chairman and CEO of IDev Technologies (Houston). Founder and former CEO, Jeffery Sheldon, will retain the position of president, chief operating officer and board member. From August 2000 to his retirement in April 2005, Tully was president and CEO of Neothermia, and also has served in those capacities at NMT Medical. IDev is a developer of minimally invasive medical devices for treating peripheral vascular disease.
• Daniel Cho has been appointed assistant managing director of Rheologics (Exton, Pennsylvania). He has been involved with the company as a consultant for more than five years. Rheologics, a subsidiary of Rheologics Technologies, is focused on the study of blood viscosity and its relationship to cardiovascular disease.
• John Rooney has been named vice president of marketing at Terumo Interventional Systems (Somerset, New Jersey). Rooney most recently was director of marketing at Roche Diagnostics. Terumo Interventional Systems, a business unit of Terumo Medical, sells a full line of guidewires, catheters, introducer sheaths, and embolization products for use in a multitude of different interventional procedures.
• Thoratec (Pleasanton, California), a maker of ventricular assist devices, reported in mid-January that Gary Burbach had been named president and CEO, effective immediately. Burbach replaces D. Keith Grossman, who has served as Thoratec’s CEO for 10 years. Grossman said in August of last year that he intended to step down from his position to pursue other professional interests. He continued to lead the company during the transition period, as well as the search for his successor. Since April 2005, Burbach had served as president and CEO of Digirad (Poway, California), a provider of cardiovascular imaging services and solid-state nuclear medicine imaging products to physician offices, hospitals and imaging centers. Prior to that, Burbach served as president and CEO of Bacchus Vascular (Santa Clara, California), a private interventional cardiovascular device company, for two years. He also has served as CEO of Philips Nuclear Medicine and prior to that for ADAC Laboratories.
• Vascular Solutions (Minneapolis) has made changes in its management team. CFO James Hennen will assume additional responsibilities as vice president of finance and corporate secretary. Hennen originally joined Vascular Solutions in 2002. Timothy Slayton has joined the company in the newly created position of controller and principal accounting officer. He most recently served as audit manager with McGladrey & Pullen. Michael Nagel, vice president of sales, has left the company to pursue other interests. Mark Valls will continue managing the company’s U.S. sales force across all product lines.